Literature DB >> 10767347

Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation.

M Cossée1, H Puccio, A Gansmuller, H Koutnikova, A Dierich, M LeMeur, K Fischbeck, P Dollé, M Koenig.   

Abstract

Friedreich ataxia (FRDA), the most common autosomal recessive ataxia, is caused in almost all cases by homozygous intronic expansions resulting in the loss of frataxin, a mitochondrial protein conserved through evolution, and involved in mitochondrial iron homeostasis. Yeast knockout models, and histological and biochemical data from patient heart biopsies or autopsies indicate that the frataxin defect causes a specific iron-sulfur protein deficiency and mitochondrial iron accumulation leading to the pathological changes. Affected human tissues are rarely available to further examine this hypothesis. To study the mechanism of the disease, we generated a mouse model by deletion of exon 4 leading to inactivation of the Frda gene product. We show that homozygous deletions cause embryonic lethality a few days after implantation, demonstrating an important role for frataxin during early development. These results suggest that the milder phenotype in humans is due to residual frataxin expression associated with the expansion mutations. Surprisingly, in the frataxin knockout mouse, no iron accumulation was observed during embryonic resorption, suggesting that cell death could be due to a mechanism independent of iron accumulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767347     DOI: 10.1093/hmg/9.8.1219

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  108 in total

Review 1.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

2.  Evaluation of an FRDA-EGFP genomic reporter assay in transgenic mice.

Authors:  Joseph P Sarsero; Timothy P Holloway; Lingli Li; Samuel McLenachan; Kerry J Fowler; Ivan Bertoncello; Lucille Voullaire; Sophie Gazeas; Panos A Ioannou
Journal:  Mamm Genome       Date:  2005-04       Impact factor: 2.957

3.  Association between trinucleotide CAG repeats of the DNA polymerase gene (POLG) with age of onset of Iranian Friedreich's ataxia patients.

Authors:  Mohammad Mehdi Heidari; Massoud Houshmand; Saman Hosseinkhani; Shahriar Nafissi; Barbara Scheiber-Mojdehkar; Mehri Khatami
Journal:  Neurol Sci       Date:  2008-11-28       Impact factor: 3.307

Review 4.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

5.  PEP-1-frataxin significantly increases cell proliferation and neuroblast differentiation by reducing lipid peroxidation in the mouse dentate gyrus.

Authors:  Woosuk Kim; Dae Won Kim; Bich Na Shin; Dae Young Yoo; Sung Min Nam; Mi Jin Kim; Jung Hoon Choi; Yeo Sung Yoon; Moo-Ho Won; Soo Young Choi; In Koo Hwang
Journal:  Neurochem Res       Date:  2011-09-01       Impact factor: 3.996

Review 6.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

7.  Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.

Authors:  R Mark Payne; P Melanie Pride; Clifford M Babbey
Journal:  Pediatr Cardiol       Date:  2011-03-01       Impact factor: 1.655

8.  Neurobehavioral deficits in the KIKO mouse model of Friedreich's ataxia.

Authors:  Marissa Z McMackin; Chelsea K Henderson; Gino A Cortopassi
Journal:  Behav Brain Res       Date:  2016-08-26       Impact factor: 3.332

Review 9.  Mitochondrial Iron in Human Health and Disease.

Authors:  Diane M Ward; Suzanne M Cloonan
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

Review 10.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.